Cerebral Substrates of Prospective Memory in Young and Its Disruption in Normal Aging and in Alzheimer's Disease: A Study in Anatomical MRI, Diffusion Tensor MRI and Functional MRI

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

178 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigators propose in this study to evaluate prospective memory (MP) in all its complexity as well as the processes, cognitive and brain, the underlying. Specifically, investigators propose to evaluate the evolution of the MP during normal aging and Alzheimer's disease (AD) to identify the cognitive and brain processes underlying this development. To do this, this study will have to include healthy subjects, 18 to 95 years, patients with Mild Cognitive Impairment (MCI) and patients with probable AD. All participants will undergo a series of examinations, both neuropsychological and brain imaging.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Memory Imaging

NCT01638884

Alzheimer Disease

UNKNOWN NA

Evaluation of Age- and Alzheimer's Disease-Related Memory Disorder

NCT00029120

Alzheimer Disease Dementia Memory Disorder +1 more

COMPLETED

Multi-modal Neuroimaging in Alzheimer's Disease

NCT01638949

Alzheimer's Disease

COMPLETED NA

Optimization of MRI Sequences Used in the Study of Neurodegenerative Diseases

NCT05929144

Memory Disorders

RECRUITING NA

Memory Imaging of Normal Aging

NCT00315575

Alzheimer's Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All participants:

* Normal Education\> 7 years
* French mother tongue
* right-handed (Edinburgh Inventory)
* score on the scale of Beck \<7 (depression scale)
* signing the informed consent of the protocol in agreement with the Committee to Protect People

Exclusion Criteria

* Young healthy subjects aged between 18 and 44 years
* Healthy subjects intermediate age: between 45 and 69 years

* score on the Mattis Dementia Scale higher than 137, in order to exclude any potential dementia
* Performance "normal" to test RI RL-16 (that is to say, not differing by more than 1.65 standard deviation from the norm for age and cultural level \[see normative values published Van der Linden et al., 2004\]), test conventionally used to assess the verbal episodic memory.
* Healthy elderly subjects aged 70 and over, living at home

* score on the Mattis Dementia Scale higher than 137, in order to exclude any potential dementia
* Performance "normal" to test RI RL-16 (that is to say, not differing by more than 1.65 standard deviation from the norm for age and cultural level \[see normative values published Van der Linden et al., 2004\]), test conventionally used to assess the verbal episodic memory.
* MCI patients: older than 50 years and recruited from memory clinics and meet the current criteria and recognized including amnestic MCI

* memory complaint
* targets deficits of episodic memory (lower performance of at least 1 standard deviation from the norm for age and cultural level to one or more (sub) episodic memory scores of diagnostic battery - cf. . Tables 1 and infra)
* performance in the standards for age and cultural level in all tests of diagnostic battery measuring other cognitive functions as memory, including the evaluation of overall cognitive ability tests.
* Alzheimer's patients: older than 50 years were recruited from the clinics and memory satisfying the standards NINCDS-ADRDA criteria for probable AD which include

* abnormal global cognitive functioning and deficits in two or more cognitive domains identified by the diagnostic battery
* mild to moderate AD (MMSE ≥ 18).

* Cognitive disorders of sudden onset (contrary to their slow and progressive onset in AD), which could reflect a stroke; a modified Hachinski ischemic score ≤ 2 (Loeb \& Gandolfo, 1983); history of head trauma with loss of consciousness for more than 1 hour, or encephalitis;
* Chronic neurological disease, psychiatric, endocrine, hepatic, infectious;
* A history of major illness (chronic lung disease, heart disorder, metabolic, hematologic, endocrine or immunological severe, cancer);
* A medication that may interfere with the mnemonic or metabolic measures (psychotropics, hypnotics, anxiolytics, neuroleptics, anti-Parkinson, benzodiazepines, anti-inflammatory drugs, antiepileptics, antihistamines, analgesics and muscle relaxants central, as is usual The investigating doctor deems the annoying character for the study of the regular intake of certain medications). Taking anticholinesterase treatment will also be a criterion for non-inclusion.
* Chronic intake of alcohol or drugs;

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes